Request Demo
Last update 10 Jul 2025
Nilvanstomig
Last update 10 Jul 2025
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms ZG-005, ZG005 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
18
Clinical Trials associated with NilvanstomigNCT07038096
A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)
NCT06927687
A Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of ZG005 in Patients With Advanced Solid Tumors
NCT06883526
A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
100 Clinical Results associated with Nilvanstomig
Login to view more data
100 Translational Medicine associated with Nilvanstomig
Login to view more data
100 Patents (Medical) associated with Nilvanstomig
Login to view more data
100 Deals associated with Nilvanstomig
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neuroendocrine Carcinoma | Phase 2 | - | 01 Aug 2025 | |
| Small Cell Lung Cancer | Phase 2 | - | 01 Aug 2025 | |
| Advanced Lung Small Cell Carcinoma | Phase 2 | China | 25 Jun 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 01 May 2025 | |
| Recurrent Lymphoma | Phase 2 | China | 28 Apr 2025 | |
| Refractory Lymphoma | Phase 2 | China | 28 Apr 2025 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 01 Apr 2025 | |
| Advanced biliary tract cancer | Phase 2 | China | 04 Mar 2025 | |
| Advanced Hepatocellular Carcinoma | Phase 2 | China | 22 Oct 2024 | |
| Advanced Neuroendocrine Carcinoma | Phase 2 | China | 24 May 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | Advanced Cervical Carcinoma First line | 41 | frzfjdrdcf(nssfnszdbx) = 1 SAE of bilateral lung pneumonia in the 10 mg/kg group was assessed related to ZG005 by the investigator dzqanugtnx (qtsdlufqkx ) | Positive | 30 May 2025 | ||
Not Applicable | 55 | hxljelufci(bqngossjgh) = Serious adverse events (SAEs) occurred in 8 subjects (14.5%), with one myositis case (1.8%) was the only SAE related to ZG005 and also the sole TRAE that led to treatment discontinuation lukrzhgyxe (dvahspajmh ) View more | Positive | 30 May 2025 | |||
CTR20220021 (NEWS) Manual  | Phase 1/2 | 46 | afcnavqiih(vlbktyesud) = ybemxqkzno iupalaeacl (apjlovdmks ) View more | Positive | 25 Sep 2024 | ||
(20 mg/kg) | afcnavqiih(vlbktyesud) = mcihqdrxvg iupalaeacl (apjlovdmks ) View more | ||||||
Not Applicable | Advanced Hepatocellular Carcinoma First line | 10 | gmlywugfid(wsuvvakuat) = ncitigycma ekmojbgmvl (rcgatieipo ) View more | Positive | 25 Sep 2024 | ||
CTR20220021 (ASCO2024) Manual | Phase 1 | 57 | fizymkqesa(zlzzqehwod) = yyrndagwzt dnosvsmrxy (octxdvymef ) View more | Positive | 24 May 2024 | ||
(cervical cancer) | fizymkqesa(zlzzqehwod) = ooeasyqscf dnosvsmrxy (octxdvymef ) View more | ||||||
Phase 1 | 16 | utmqfzqddx(nkdbubviqz) = qnstxtvatl pkoxfngpvw (ngarzunznf ) View more | Positive | 26 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free